Biomarker spinout founded by Dunn School alumni holds successful flotation on AIM

Biomarker spinout founded by Dunn School alumni holds successful flotation on AIM

Oxford Biodynamics, a biomarker company set up by former Dunn School researchers Dr Alexandre Akoulitchev and Dr Aroul Ramadass, completed a successful flotation on AIM, the London Stock Exchange’s international market for smaller growing companies, on 6 December 2016.

Spun out in 2007 by Oxford University Innovation, the company has commercialised technological breakthroughs in a new generation of biomarkers for cancer and other diseases.

Its main platform, EpiSwitch, utilises Biodynamics’ biomarker evaluating technology to increase the success rates of drugs pass Phase I clinical trials. The company raised £20m ahead of its flotation, and has been trading steadily around the 160p mark.

For more on Oxford Biodynamics, please visit: http://www.oxfordbiodynamics.com/

For more on the flotation, please visit Proactive Investors or Shares Magazine.

Monday, December 19, 2016 - 15